Clonal analysis of invasive pneumococcal isolates in Scotland and coverage of serotypes by the licensed conjugate polysaccharide pneumococcal vaccine: possible implications for UK vaccine policy

A 7-valent pneumococcal conjugate vaccine (PCV7) has gained licensure and has proven successful in the USA for preventing pneumococcal disease and reducing the incidence of antibiotic-resistant pneumococcal strains. The ability, therefore, to accurately monitor the likely effect of the introduction of PCV7 vaccine on invasive pneumococcal disease in the UK is essential. Serotyping and multilocus sequence typing was performed on invasive isolates of Streptococcus pneumoniae (n=645) from Scotland during 2003. The information gained from this was used to evaluate serotype coverage by the vaccine and the relationship between serotypes. In the present study, invasive pneumococcal disease in Scotland was caused by 33 different serotypes, consisting of 150 sequence types. Overall, 48.4% of the isolates were of serotypes included in the PCV7. Pneumococci were most frequently associated with sequence types 9, 124, and 162. PCV7 would provide protection in 71.8% of infants under 5 years of age against the serotypes in the vaccine. There was limited evidence of the potential for capsule switch among currently circulating invasive pneumococci. The successful implementation of a suitable vaccination programme should lead to a reduction in invasive pneumococcal disease in the UK as well as a reduction in antibiotic resistance of pneumococcal strains.

[1]  H. Campbell,et al.  Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies , 2000, Epidemiology and Infection.

[2]  R. Dagan,et al.  Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers , 2003, The Pediatric infectious disease journal.

[3]  L. Smart.  Serotyping of Streptococcus pneumoniae strains by coagglutination. , 1986, Journal of clinical pathology.

[4]  S. Clarke,et al.  Serotypes and Sequence Types of Pneumococci Causing Invasive Disease in Scotland Prior to the Introduction of Pneumococcal Conjugate Polysaccharide Vaccines , 2004, Journal of Clinical Microbiology.

[5]  S. Obaro,et al.  Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants , 2000, The Pediatric infectious disease journal.

[6]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[7]  B. Spratt,et al.  Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. , 2003, The Journal of infectious diseases.

[8]  B. Spratt,et al.  Stability of Serotypes during Nasopharyngeal Carriage of Streptococcus pneumoniae , 2003, Journal of Clinical Microbiology.

[9]  M. A. Diggle,et al.  Semiautomation of Multilocus Sequence Typing for the Characterization of Clinical Isolates of Neisseria meningitidis , 2001, Journal of Clinical Microbiology.

[10]  D. Robinson,et al.  Evolution and Virulence of Serogroup 6 Pneumococci on a Global Scale , 2002, Journal of bacteriology.

[11]  J. M. Smith,et al.  Estimating recombinational parameters in Streptococcus pneumoniae from multilocus sequence typing data. , 2000, Genetics.

[12]  R. Dagan,et al.  Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. , 1997, The Pediatric infectious disease journal.

[13]  R. Huebner,et al.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. , 1999, The Journal of infectious diseases.

[14]  N. Andrews,et al.  Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis , 2003, BMJ : British Medical Journal.

[15]  S. Black,et al.  Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine , 2001, The Pediatric infectious disease journal.

[16]  R. Dagan,et al.  Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. , 2002, The Journal of infectious diseases.

[17]  A. Tomasz,et al.  Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo. , 1998, The Journal of infectious diseases.

[18]  B. Spratt,et al.  Prevention of pneumococcal disease by vaccination: does serotype replacement matter? , 2000, The Lancet.

[19]  P. Christie,et al.  The impact of meningococcal serogroup C conjugate vaccine in Scotland. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  B. Spratt,et al.  A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. , 1998, Microbiology.

[21]  C. Whitney,et al.  Clonal Distribution of Invasive Pneumococcal Isolatesfrom Children and Selected Adults in the United States Prior to7-Valent Conjugate VaccineIntroduction , 2003, Journal of Clinical Microbiology.

[22]  H. Campbell,et al.  Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Achtman,et al.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[25]  G. Siber,et al.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Maiden,et al.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination , 2002, The Lancet.

[27]  S. Obaro,et al.  Carriage of pneumococci after pneumococcal vaccination , 1996, The Lancet.

[28]  B. Spratt,et al.  Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae , 1998, Molecular microbiology.

[29]  D. Greenberg,et al.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[30]  S. Clarke,et al.  Automated pneumococcal MLST using liquid-handling robotics and a capillary DNA sequencer , 2003, Molecular biotechnology.

[31]  Ron Dagan,et al.  The potential indirect effect of conjugate pneumococcal vaccines. , 2003, Vaccine.

[32]  M. Osterholm,et al.  Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. , 1993, JAMA.